Announcements

30AUG

Virtus ETF Solutions Rebrands BioShares ETFs; Moves Listings for BBC, BBP to NYSE Arca

Virtus ETF Solutions Rebrands BioShares ETFs; Moves Listings for BBC, BBP to NYSE Arca NEW YORK, Aug. 30, 2017 /PRNewswire/ -- Virtus ETF Solutions, an affiliate of Virtus Investment Partners, Inc. (NASDAQ:VRTS) and multi-manager ETF sponsor, today announced that effective September 1, 2017, the BioShares Biotechnology Clinical Trials Fund (Ticker: BBC) and the BioShares Biotechnology Products Fund (Ticker: BBP) will change their names to the Virtus LifeSci Biotech Clinical Trials ETF and the Virtus LifeSci Biotech Products ETF, respectively, and will change their primary listing venue to NYSE Arca. The funds, which are advised by Virtus ETF Advisers, will retain their current ticker symbols when they
16JUN

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition

New York, June 16, 2017 — LifeSci Index Partners, LLC, an affiliate company of LifeSci Advisors, and a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShares Biotechnology exchange-traded funds (ETFs), which trade under the symbols BBC and BBP on Nasdaq. These passively-managed funds are designed to track their respective, rules-based indexes. 
01MAR

LifeSci Biotechnology Clinical Trials Index - Removal of CLCD

20FEB

LifeSci Biotechnology Products Index - Removal of ARIA

16DEC

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition

New York, December 16, 2016 — LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShares Biotechnology exchange-traded funds (ETFs), which trade under the symbols BBC and BBP on Nasdaq. These passively-managed funds are designed to track their respective, rules-based indexes. 
16JUN

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition

The BioShares Biotechnology Funds are the only ETFs to separate Clinical Trials stage companies and Products stage companies into two distinct funds. The BioShares Biotechnology Clinical Trial Fund (BBC) and BioShares Biotechnology Product Fund (BBP) offer investors exposure to these two distinct segments of the biotechnology sector while diversifying some of the risks associated with any single company.
21DEC

BioShares Biotechnology Funds Announce Distribution

For Further Information: Virtus ETF Solutions etfinfo@virtus.com   BioShares™ Biotechnology Products Fund and  BioShares™ Biotechnology Clinical Trials Fund Announce Distribution   New York, NY, December 21, 2015 – The BioShares™ Biotechnology Products Fund (Ticker: BBP) and BioShares™ Biotechnology Clinical Trials Fund (Ticker: BBC), exchange-traded funds advised by Virtus ETF Advisers, LLC and subadvised by LifeSci Index Partners, LLC, today announced a distribution on its common stock as follows: Ticker Per-Share Distribution Declaration Date Ex-Date Record Date Payable Date BBP $0.39725 12/18/2015 12/21/2015 12/23/2015 12/29/2015 BBC $0.14733 12/18/2015 12/21/2015 12/23/2015 12/29/2015   About the funds The BioShares™ Biotechnology Products Fund and BioShares™ Biotechnology Clinical Trials Fund seek investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index and the LifeSci
16DEC

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition; Celebrate 1-Year Anniversary

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition; Celebrate 1-Year Anniversary (Nasdaq: BBC, BBP) BioShares Biotechnology Funds Celebrate 1-Year Anniversary New York, December 16, 2015 — LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShares Biotechnology exchange-traded funds (ETFs), which trade under the symbols BBC and BBP on Nasdaq. These passively-managed funds are designed to track their respective, rules-based indexes. The BioShares Biotechnology Funds are the only ETFs to separate Clinical Trials stage companies and Products stage companies into two distinct funds. The BioShares Biotechnology Clinical Trial
26AUG

Important Notice on Daily NAV Calculation

NOTE: Since August 24th, the Funds’ third-party administrator has been experiencing technical issues with its fund accounting software impacting its ability to calculate NAV for its ETF clients, including the Funds. As a result, the NAV we are presenting here for the Funds is the closing indicative NAV of the Funds, which represents the best available information at this time. Upon correction of the problem, these indicative NAVs will be compared to actual values, adjustments will be made and shareholders will be notified as required. Please contact the Virtus ETF Advisers help desk at 888-383-0553 for more information.
16JUN

BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition

Following rebalance, BBC and BBP funds offer increased diversity of holdings
04MAR

BioShares Rings Nasdaq Opening Bell - VIDEO

 
02MAR

BioShares ETFs to Ring The Nasdaq Stock Market Opening Bell on March 4, 2015

The BioShares ETF team will visit the Nasdaq MarketSite in Times Square to celebrate the listing of the BBC and BBP ETFs and ring the Opening Bell
17DEC

BioShares Launches Two New Biotechnology ETFs (Nasdaq: BBC, BBP)

BioShares Launches Two New Biotechnology ETFs (Nasdaq: BBC, BBP) BioShares Biotechnology Funds give investors unique and selective exposure to the dynamic, high-growth biotechnology sector New York, December 17, 2014 — LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today launched the BioShares™ Biotechnology Clinical Trials Fund (Nasdaq: BBC) and the BioShares™ Biotechnology Products Fund (Nasdaq: BBP) (together, “the Funds”).  The Funds are designed by a team of biotechnology investment specialists and allow investors, for the first time, to choose from two distinct groups of stocks that are typically grouped together in other funds – advanced products stage
NextPrevious